Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Urology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 60%GRADE not reported 0 · 0%Very low 1 · 20%Low 0 · 0%Moderate 0 · 0%High 1 · 20%

Intervention not reported

Quality of life (QoL) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…

The review found no eligible studies for this question.

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Quality of life (QoL) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…

The review found no eligible studies for this question.

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serenoa repens vs placebo or no intervention

QoL · men with lower urinary tract symptoms secondary to benign prostatic obstruction

Serenoa repens showed no clear difference in quality of lifeMeasured by IPSS‐QoL score (range 0 to 6) compared with placebo or no intervention (high certainty).

1 finding from 1 review

Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1001 participants
High

Serenoa repens in combination with other phytotherapy vs placebo or no intervention

QoL · men with lower urinary tract symptoms secondary to benign prostatic obstruction

1 finding from 1 review

Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 265 participants
Very low

Intervention not reported

Quality of life (QoL) We reported this outcome narratively in this review. Here, long‐term results (i.e., at the end of treatment) are presented. In the comparison PAZ versus SUN, QoL was measured using FACIT‐F (score range 0‐52; higher scores rep... · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy

The review found no eligible studies for this question.

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found